News & Media
SK life science
Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company
General business
Strategic alliance and partnership opportunities
Media inquiries and PR
Grant and investigator initiated proposals
Sponsorship requests
Medical information inquiries or report adverse events
Phone: 1-866-OKSKLSI (657-5574)
Email: medicalinfo@sklsi.com
SK life science at a glance
-
Headquarters location
PARAMUS, NJ
-
R&D Begins
1993
-
Parent Company
SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group
-
Number of employees
200+ EMPLOYEES
-
Disease Category Focus
CNS
-
Pipeline
8 compounds under clinical development
Newsroom
6/22/2022
Long-Term Efficacy and Safety Data of XCOPRI® (cenobamate tablets) CV Published in Neurology
Full release5/25/2022
SK Biopharmaceuticals Announces Social Value Performance for 2021
Full release5/19/2022
SK Biopharmaceuticals Partners with Cala to Fuel Innovation in Neurology
Full release3/31/2022
SK life science Presents Long-term Data on Cognitive and Psychiatric Adverse Events Associated with XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AAN 2022 Annual Meeting
Full release3/23/2022
SK life science to Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Academy of Neurology 2022 Annual Meeting
Full release2/24/2022
SK Biopharmaceuticals Becomes First Korean Company to Join Pharmaceutical Supply Chain Initiative
Full release1/13/2022
SK life science Announces FDA Clearance of IND Application for its Oncology Candidate, SKL27969, a PRMT5 Inhibitor for the Potential Treatment of Advanced Solid Tumors
Full release1/06/2022
SK life science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome
Full release12/23/2021
SK Biopharmaceuticals Enters into Licensing Agreement with Endo for Cenobamate in Canada
Full release12/03/2021
SK life science Presents Long-Term Data of XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset Seizures at the American Epilepsy Society 2021 Annual Meeting
Full release